A taxane derivative, TPI 287 (abeotaxane), was developed with excellent BBB penetrance, and underwent testing in oncologic trials for brain metastases. [122] TP 287 has also been proposed as a microtubule stabilizer that may have efficacy in tauopathies, and this hypothesis has led to two Phase 1 studies looking at safety and tolerability in 44 CBS or PSP patients (NCT02133846) and 33 mild to mod AD patients (NCT01966666). Both trials ended in 2017, and immune hypersensitivity reactions limited dosing in the AD arm, and a dose-related worsening of falls and cognitive outcomes was found in the 4R-tauopathy cohort, and this agent is no longer in clinical development [123].
